Inside Pnc Financial Services Group INC’s Q1 2026 Rotation

The biggest dollar adds tell a very simple story: they believe the easy US mega-cap trade is behind us, and the next leg of returns will come from ex-US catch-up, AI’s second wave, and riskier parts of the equity spectrum.

They don’t show new single-stock heroes; instead, they scale existing themes:

• IDEV (iShares Core MSCI International Developed) is the single largest add, up 38.6% with about $385.2M of capital, a blunt but clear bet that developed ex-US is too cheap relative to the US.
• AIQ (Global X Artificial Intelligence & Technology) jumps 16.5%, roughly $179.9M more into a dedicated AI sleeve rather than just relying on the FAANG complex inside broad benchmarks.
• IEMG (iShares Core MSCI Emerging Markets) climbs 9.2%, adding about $88.5M, pushing the book further into higher-volatility EM beta.
• NVDA sees another 3.4% share increase and about $63.6M more, even after a gain vs average cost of 167.5%, signaling they still see upside in the core AI hardware winner.
• DFIV (Dimensional International Value) is up 6.3% (~$51.8M), a pure factor expression that ex-US value can finally work.
• IWM (Russell 2000) gets 6.6% more shares (~$48.9M), a clear move toward small-cap risk after a correction.
• AGG and GOVT together bring in about $85.1M of fresh capital, showing they want dry powder and ballast even as they reach for equity risk elsewhere.

Put together, the adds read like a conviction call on global and AI-driven dispersion: more ex-US, more small caps, more explicit AI, but cushioned with high-quality fixed income.

The sells are not a wholesale de-risking; they are a reshuffle out of undifferentiated US exposure and some aging defensives to pay for more pointed bets.

The biggest funding block is straightforward:

• SPY is cut by 4.0%, freeing about $105.6M, a clear willingness to own the S&P 500 less directly.
• IVV, another core S&P 500 tracker, is trimmed slightly (down 0.5%, roughly $55.0M), pushing in the same direction.
• QUAL and DGRW, both quality- and dividend-tilted US equity ETFs, are trimmed by 4.8% and 5.0%, taking out a combined ~$112.8M; that’s a quiet vote that defensive quality has gotten crowded and fully priced.
• IJR and IQLT, representing US small-cap core and international quality, lose 4.9% and 5.1% of shares; instead of vanilla small caps and quality screens, the manager is favoring more targeted vehicles like IWM and DFIV.

On the single-name side, the moves are surgical, not thematic:

• JNJ is cut 3.9% (about $56.8M) while Lilly remains untouched, reinforcing Lilly as the chosen pharma growth engine and JNJ as a source of cash.
• Berkshire Hathaway is trimmed modestly despite being up nearly 992.8% vs average cost, a classic “harvest gains from the compounding machine” move, not a repudiation.

In effect, they are exiting the middle ground: less generic US quality and small-cap beta, more deliberate expressions of where they think the next cycle’s winners reside.

On the surface, sector weights barely budge: health care nudges from 42.69% to 42.54%, technology holds at 13.25%, and the other classified sectors move by only a few basis points. That stability is deceptive; the real rotation is happening inside the large “unclassified” ETF bucket that now sits at 33.88%.

Within that ETF block, capital is clearly flowing out of broad US and into foreign and factor sleeves. Cuts to SPY, IVV, QUAL, DGRW, IJR, and IWD are offset by larger adds to IDEV, IEMG, DFIV, and IWM, which collectively push more of the book into developed ex-US, emerging markets, international value, and small caps.

Technology exposure via single names is subtly re-optimized rather than expanded. NVDA and AIQ get fresh money, while AAPL and MSFT see tiny trims and Alphabet and Meta get fractional adds, leaving overall tech weight flat but with a tilt toward AI infrastructure and AI-themed ETFs.

Energy is essentially unchanged, with a small rotation from Exxon (trimmed 1.3%) toward Chevron (up 0.6%), while financials see marginal de-risking via JPM. The giant outlier remains Eli Lilly at 27.26% of the entire book, making health care the de facto macro call regardless of what happens at the margin in other sectors.

This quarter’s changes read like a manager who thinks the regime has shifted: the US mega-cap, quality-heavy one-way trade is tired, and the next three years of excess return will be driven by ex-US normalization, AI-driven capex cycles, and a more volatile small-cap backdrop.

The portfolio still leans heavily on Eli Lilly as its growth spine and keeps a full complement of broad US index ETFs for baseline exposure. But the incremental dollar is no longer buying “the market”; it is buying specific edges — developed ex-US, EM, international value, small caps, and focused AI — with Treasuries and core bonds added as a stabilizer.

If they are right, this book is now better tuned for dispersion and factor rotation than for a straight beta melt-up. If they are wrong and US large-cap growth resumes uncontested leadership, the trims in SPY, IVV, quality, and some US small-cap core could lag the simplest S&P 500 play.

Either way, the message from the 13F is clear: Pnc Financial Services Group INC is done hiding in broad US benchmarks. The portfolio is being nudged toward a more opinionated, globally diversified, and AI-aware stance, with enough fixed income to ride out the volatility that stance implies.